title: Lutetium-177 Labeled Therapeutics: ¹⁷⁷Lu-PSMA is Set to Redefine Prostate Cancer Treatment.
authors.forename: Ambikalmajan M R
authors.initials: AM
authors.lastname: Pillai
authors.affiliation: Oak Ridge, Tennessee, USA. knappffjr@ornl.gov.
authors.forename: Furn F Russ
authors.initials: FF
authors.lastname: Knapp
mesh_terms: D000954:Antigens, Surface / Q000008:administration & dosage; D043425:Glutamate Carboxypeptidase II / Q000008:administration & dosage; D006801:Humans; D008187:Lutetium / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011868:Radioisotopes / Q000008:administration & dosage; D019275:Radiopharmaceuticals / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D000954:Antigens, Surface; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D008187:Lutetium; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II